These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28123783)

  • 1. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis.
    Huynh DH; Boyd TA; Etzel CJ; Cox V; Kremer J; Mease P; Kavanaugh A
    RMD Open; 2017; 3(1):e000395. PubMed ID: 28123783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
    Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
    Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
    Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
    RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.
    Mease PJ; Collier DH; Saunders KC; Li G; Kremer JM; Greenberg JD
    RMD Open; 2015; 1(1):e000181. PubMed ID: 26819748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    J Rheumatol; 2018 Jan; 45(1):78-82. PubMed ID: 28966209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
    Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
    Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.
    Ogdie A; Palmer JL; Greenberg J; Curtis JR; Harrold LR; Solomon DH; Kavanaugh A; Kremer JM; Mease PJ
    J Rheumatol; 2019 May; 46(5):475-482. PubMed ID: 30647182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
    Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
    Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.
    Mease PJ; van der Heijde D; Karki C; Liu M; Park Y; Greenberg JD
    Rheumatol Ther; 2018 Dec; 5(2):537-550. PubMed ID: 30353387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.
    Mease PJ; Lesperance T; Liu M; Collier DH; Mason M; Deveikis S; Accortt NA
    J Rheumatol; 2017 Feb; 44(2):184-192. PubMed ID: 28089969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
    Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
    Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.
    Højgaard P; Glintborg B; Hetland ML; Hansen TH; Lage-Hansen PR; Petersen MH; Holland-Fischer M; Nilsson C; Loft AG; Andersen BN; Adelsten T; Jensen J; Omerovic E; Christensen R; Tarp U; Østgård R; Dreyer L
    Ann Rheum Dis; 2015 Dec; 74(12):2130-6. PubMed ID: 25063827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
    Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study.
    Clunie G; McInnes IB; Barkham N; Marzo-Ortega H; Patel Y; Gough A; Packham J; Kyle S; Kirkham B; Sheeran T; Coope H; Bishop-Bailey A; McHugh N
    Rheumatol Adv Pract; 2018; 2(2):rky042. PubMed ID: 31431979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.
    Emamikia S; Arkema EV; Györi N; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven R
    RMD Open; 2016; 2(2):e000323. PubMed ID: 27651929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
    Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
    Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.
    Fagerli KM; Kearsley-Fleet L; Watson KD; Packham J; Contributors Group BR; Symmons DPM; Hyrich KL
    RMD Open; 2018; 4(1):e000596. PubMed ID: 29479475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
    Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
    J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.